GlaxoSmithKline Pharmaceuticals is a century-old Indian subsidiary of a British biopharma giant that works at both ends of the healthcare spectrum - preventing disease through vaccines and treating it through branded medicines - reaching more than 270 million Indians every year. Incorporated in 1924 and listed since 1969, the company has built its position by sticking to areas where it can hold a differential advantage and create mega brands rather than chasing small, scattered opportunities. That philosophy runs through everything: a general medicines portfolio anchored by household names, a vaccines business that leads the private market, and a young specialty arm built on innovative global therapies brought to India with shrinking launch delays.
Business segments
Three engines at different stages - a general medicines cash cow built on decades-old doctor trust, a vaccines franchise that dominates private-pay immunisation, and a specialty bet on imported innovation that is still finding its feet.
1. General Medicines: the bedrock of doctor trust and pharmacy shelves
A portfolio of established brands - led by the country’s most prescribed antibiotic and painkiller - that reaches four in five prescribing doctors and grows ahead of the market because it owns the top slot in anti-infectives and dermatology.
- Seven brands in the national top 100 - Augmentin, Calpol, Betnovate-C, Betnovate-N, Ceftum, Eltroxin, and T-bact all rank among India’s hundred largest pharmaceutical brands, and 15 brands cross Rs. 1,000 million in annual turnover. That breadth means 80% of prescribing healthcare professionals write at least one GSK brand, giving the sales force a ready conversation with almost every doctor in the country.
- The antibiotic that anchors the house - Augmentin is the No. 1 brand in the Indian Pharmaceutical Market (IPM) and the most widely prescribed antibiotic, used for everything from respiratory infections to surgical prophylaxis. A tougher formulation, Augmentin ES, targets penicillin-resistant bacteria and is now made locally to cut import dependence.
- Pain and skin leadership - Calpol commands nearly a third of India’s paracetamol market, making it the leader in the plain paracetamol market. In dermatology, the company holds the top position across the three largest segments, with T-bact alone capturing a 27% prescription share among topical antibiotics and Betnovate leading topical corticosteroids since 1963.
- A sales engine built for reach, not overlap - Over 2,000 field representatives cover 360,000-plus healthcare professionals across more than 1,400 towns, supported by digital channels that now account for 76% of all doctor interactions. The company switched to a prescriber-centric model so that fewer reps call on the same doctor, freeing capacity to push into tier-two to tier-four markets.
- One factory, many partners - The Nashik plant churns out roughly 4.8 billion tablets and 150 million tubes a year, covering more than a third of general medicines revenue, while 19 contract manufacturers produce the rest. A fire at a key contract site disrupted supply, with the last residual impact in Q4 of the financial year, so the company is now diversifying its supplier base.
2. Vaccines: the private-market leader in childhood and adult immunisation
A GSK vaccine is given to an Indian infant every seven seconds, and the company holds a 20.9% value share of the private vaccines market - built on a paediatric portfolio that has led for over 40 years and an adult shingles shot that is creating a new category.
- Paediatric vaccines as the steady anchor - Brands like Infanrix Hexa, a six-in-one combination shot, hold roughly 60% of the hexavalent category, while the pneumococcal vaccine Synflorix has kept its leadership for over 12 years. The paediatric portfolio grew 9% in FY2025-26, with double-digit performance in the final quarter.
- Shingrix is building adult immunisation from scratch - The recombinant shingles vaccine for adults over 50 generated 55,000 prescriptions with 56% year-on-year growth, supported by a dedicated team of over 200 people and a prescribing community of nearly 1,400 doctors across specialties. The company trained 700 paramedics and partnered with over 700 clinics to turn them into adult vaccination centres, because the category barely exists in India today.
- VaxiKart locks in paediatricians - An industry-first online ordering app lets doctors manage vaccine inventory and buy from their preferred distributors; it now captures 45% of paediatric vaccine revenue and has signed up 12,000 healthcare professionals covering 80% of India’s paediatricians. That digital plumbing makes switching costly for competitors.
- Imported, so structurally lower-margin - Unlike general medicines, vaccines and specialty products are brought in from global supply chains, which means they earn thinner margins than locally made tablets and creams. The trade-off is access to globally patented products that local players cannot copy.
3. Specialty: the innovation bet on respiratory and oncology
A young, import-driven portfolio contributing nearly 6% of revenue, built by bringing global first-in-class therapies to India faster - and already treating over 30,000 respiratory patients while planting a flag in oncology with two launches in 2025.
- Trelegy holds its ground against generics - India’s first once-daily single-inhaler triple therapy for COPD operates in a market growing at 59% and has expanded its prescription share to 12% even after losing exclusivity, supporting more than 30,000 patients. The brand sustained share despite copycat competition, suggesting doctors stick with the original.
- Nucala treats what no other biologic can - It is the only biologic approved in India for three separate eosinophilic conditions, and over 2,250 patients have been treated since launch, with an autoinjector version now enabling self-administration at home. The patient base is still small - roughly 100 to 120 new patients a month - but each one represents a chronic, recurring revenue stream.
- Oncology arrived in a single quarter - Zejula (an oral PARP inhibitor for ovarian cancer) and Jemperli (India’s first PD-1 immunotherapy for endometrial cancer) both launched in August 2025, and within months the company secured approval for a first-line endometrial cancer trial that expanded the eligible patient pool roughly 7.5 times, from about 800 to approximately 6,000. A patient support programme called Phoenix helps patients afford these therapies.
- A pipeline tethered to global trials - The company is running 26 clinical studies in India, including 14 in oncology and 8 in respiratory and immunology, many of them part of global programmes so that Indian patients get access closer to worldwide launch dates. The next expected launch is Blenrep, an antibody-drug conjugate for multiple myeloma, which has received marketing authorization and will be launching very soon.
Group structure and partners
A 75%-held subsidiary of UK-based GSK plc, with no debt, a single owned factory, and a global capability centre in Bengaluru that supports the parent’s worldwide R&D and operations.
- Parentage brings pipeline, not just capital - GSK plc’s 75% indirect holding means the Indian company gets first call on global innovative assets like Jemperli and Shingrix, while the Bengaluru global capability centre, set up in 2021, handles enterprise functions and pharmaceutical R&D for the group worldwide.
- Asset-light by design - The company carries no borrowings and runs just one owned manufacturing site at Nashik, with roughly two-thirds of products made by contract manufacturers. It sold a greenfield Karnataka factory in 2021 without ever starting commercial production there, after a global ranitidine recall killed the planned output.
- A clean-up of the brand cupboard - The Iodex and Ostocalcium trademarks were sold to a group affiliate in 2022 for Rs. 1,649 crore, while the vaccines business of another GSK Asia entity was absorbed for a nominal sum, leaving the company focused squarely on its three core verticals.